Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O76090
UPID:
BEST1_HUMAN
Alternative names:
TU15B; Vitelliform macular dystrophy protein 2
Alternative UPACC:
O76090; A8K0W6; B7Z3J8; B7Z736; O75904; Q53YQ9; Q8IUR9; Q8IZ80
Background:
Bestrophin-1, known by its alternative names TU15B and Vitelliform macular dystrophy protein 2, plays a crucial role in forming calcium-sensitive chloride channels, with a high permeability to bicarbonate. This protein's unique function is pivotal in maintaining cellular ion homeostasis.
Therapeutic significance:
Bestrophin-1 is implicated in several ocular disorders, including Macular dystrophy, vitelliform, 2, and Retinitis pigmentosa 50, highlighting its potential as a target for therapeutic intervention. Understanding the role of Bestrophin-1 could open doors to potential therapeutic strategies, offering hope for patients suffering from these debilitating conditions.